SARS-CoV-2-specific immune responses after COVID-19 vaccination in solid organ transplant recipients
Phase 4
Completed
- Conditions
- COVID-19Humoral immunity, cell-mediated immunity, COVID-19, immunocompromised
- Registration Number
- TCTR20210523002
- Lead Sponsor
- Faculty of Medicine Ramathibodi Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 250
Inclusion Criteria
All adult kidney, liver, heart transplant recipients
Exclusion Criteria
Active infection or allograft dysfunction
Previous COVID-19 vaccination
Allergic to COVID-19 vaccine
Previous COVID-19 infection
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Immunogenicity 4 weeks after the second shut of the vaccine SARS-CoV-2 neutralizing antibody
- Secondary Outcome Measures
Name Time Method Safety 1 month Monitoring